Boan Biotech (06955.HK): BA1302 approved to conduct clinical trials in the United States.

The SmartFinance APP reported that BeiGene (06955.HK) announced that its independently developed targeted CD228 innovative antibody-drug conjugate BA1302 has received approval from the U.S. Food and Drug Administration to conduct clinical trials. BA1302 is intended for the treatment of various solid tumors and has previously been granted orphan drug designation for squamous non-small cell lung cancer and pancreatic cancer by the FDA. It is currently undergoing phase I clinical trials in the People's Republic of China and is ahead of other similar research and development globally.